Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.69-
QQQ
710.930.81%
BTC/USD
77878.000.8697%
DIA
529.160.45%
GLD
401.251.76%
TLT
81.750.55%

Allarity Therapeutics Inc

ALLRNASDAQ
Trade with Public
Trade with Public
$1.41
N/A
At close: Aug 28, 5:00 PM EST
$1.39
-0.0179-1.27%
Pre-Market: 4:07 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

Allarity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Allarity Therapeutics (ALLR).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$10Upside to Avg. PT+636.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 8, 2026Ascendiant CapitalEdward WooPT RaiseBuy$10→$10
Apr 10, 2026Ascendiant CapitalEdward WooPT RaiseBuy$10→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.
Benzinga Newsdesk

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

PRO
Ascendiant Capital Initiates Coverage On Allarity Therapeutics with Buy Rating, Announces Price Target of $9

Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s “Liberation Day”, the term he’s used for April 2nd, the day of incoming reciprocal tariffs, preceded a drop in stock prices.
Rishabh Mishra

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved